explore -WSS

explore

author：Wikipedia 2025-10-01 01:50:38 - browse：44

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： PBM executives asked to testify by House panel

hotspot

WSS

Wellcome Trust names Røttingen as its new CEO

STAT Readout Newsletter: Today in biotech, life science news

Nick Jonas talks about managing diabetes along with his career

Peter Marks talks Operation Warp Speed for Rare Diseases

Peter Marks talks Operation Warp Speed for Rare Diseases

AltruBio raises $225 million to develop ulcerative colitis drug

focus

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

focus

In age of alternative facts, a scholarly course on calling out crap

European regulators consider appeal over Amylyx ALS drug

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: Merger Mondays, Ozempic panic

As demand for Covid shots wanes, Moderna seeks its next success

The effects of a landmark ruling on DNA ownership are becoming clearer

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare to cover more brain scans related to Alzheimer’s drugs

After affirmative action ruling, medical educators look to 'holistic review'

STAT Readout Newsletter: Today in biotech, life science news

focus

As health system earnings go up, health insurance stocks go down

As billionaires fund anti

There’s no way to know how good AI health technologies are

Readout LOUD podcast: Merger Mondays, Ozempic panic

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

How clinical AI models' predictive power can degrade over time

hotspot

hotspot

knowledge

entertainment